Extent of Role: Anti-Diabetic Medications
10.4093/jkd.2022.23.3.153
- Author:
Jun Hwa HONG
1
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea
- Publication Type:Opinion
- From:Journal of Korean Diabetes
2022;23(3):153-156
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In management of diabetes, glucose lowering is the basic target of treatment. Insulin is essential to type 1 diabetes. Non-insulin therapy in type 2 diabetes is very diverse and continuously developing to improve glucose control and prevent diabetes-related complications. In the recent 30 years, recommended specifications of anti-diabetic drugs are high glucose-lowering efficacy, low risk of hypoglycemia, less burden of weight gain, and cardiovascular safety. With development of SGLT2 inhibitors (sodium glucose cotransporter 2 inhibitors) and GLP-1RA (glucagon-like peptide-1 receptor agonist), the clinical benefits also include risk reduction of diabetes-related complications (hospitalization for heart failure, chronic kidney disease, atherosclerotic cardiovascular disease), even in non-diabetic patients. Anti-diabetic medication can have a role in holistic management for prevention and treatment of diabetes and diabetes-related complications, as well as an improvement of mortality.
